2A Pharma

What 2A Pharma does

2A Pharma AB is a clinical-stage Swedish/Danish biopharmaceutical company founded on December 12, 2016, developing novel prophylactic and therapeutic vaccines based on its proprietary Adeno-Associated Virus-Like Particle (AAVLP) platform. The company operates from Malmö, Sweden (parent 2A Pharma AB, registration 559090-2788) and Aalborg, Denmark (operating entity 2A Pharma ApS, CVR 3939 1597) with 1-10 employees, and holds worldwide exclusive rights to the AAVLP technology in-licensed from Medigene AG in 2016. The AAVLP platform uses non-infectious protein scaffolds derived from AAV2 that mimic virus structure without containing viral genomic material, with two immunogenic capsid positions (453 and 587) enabling monovalent and bivalent vaccine design, B-cell receptor cross-linking, conversion of low-immunogenic peptides into immunogenic antigens, and pre-existing Th-cell immune response boosting from population-wide AAV2 seropositivity.

The company's lead candidate is 2AP01 (AAVLP-HPV), a prophylactic HPV vaccine that completed a UK MHRA-approved Phase 1 clinical trial in 2020 and is positioned as the only L2-based HPV vaccine in clinical testing, claiming broader coverage than approved vaccines across alpha and beta HPV types. Its second disclosed asset, 2AP07 (AAVLP-EpCAM+), is a pre-clinical therapeutic vaccine for EpCAM+ cancers including head and neck, breast, colon, pancreatic and prostate cancers, developed in partnership with Danish Technological Institute and DNASense and supported by a EUR 653,000 Eurostars grant. The company also references pan-coronavirus and pan-Ebola vaccine collaborations with the Galveston National Laboratory and Stony Brook University, and exploratory autoimmune-disease work (vitiligo).

2A Pharma is pre-revenue and is monetizing the platform through future licensing, co-development, and outright commercialization pathways rather than current product sales. Revenue is expected upon regulatory approval and commercialization, with the option of licensing or partnership upfront payments in the interim. The company has raised cumulative seed funding of approximately EUR 7.9m from family offices (SEK 27m in 2016, USD 3m in 2018, plus additional capital through 2021) and is currently seeking Series A investment of EUR 15-20m to fund Phase 2 studies and IND progression, with plans for a Series B or IPO targeted for 2024. Customer-facing end markets in scope span patients at risk of HPV-related cancers (target market approximately USD 5.6 billion by 2023), EpCAM+ cancer patients (head and neck cancer market ~USD 1.3 billion, breast cancer drugs market projected to grow from USD 15.4 billion in 2020 to USD 31.1 billion in 2028), and autoimmune disease populations.

Name

2A Pharma

Legal name

2A Pharma ApS

Website

https://2apharma.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

2A Pharma is a clinical-stage Swedish/Danish biopharmaceutical company developing prophylactic and therapeutic vaccines based on its proprietary AAVLP virus-like particle platform, targeting HPV-related cancers, EpCAM+ cancers, and selected infectious and autoimmune diseases.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)

Keywords

• Vaccine development
• Biopharmaceutical research
• HPV cancer vaccines
• Virus-like particles
• Immunotherapy platform

Headquarters

HQ city

Malmö

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Vaccine Development and Commercialization: Pre-revenue clinical-stage company developing prophylactic and therapeutic vaccines. Currently in Phase 1 trials for HPV vaccine (2AP01). Seeking Series A investment of EUR 15-20m for Phase 2 studies and IND-ready progression. Revenue expected upon regulatory approval and commercialization of vaccine candidates.
2. Partnership and Licensing Revenue: The company holds worldwide exclusive rights to the AAVLP technology platform and may generate revenue through licensing agreements, co-development partnerships, and strategic collaborations with larger pharmaceutical companies for specific vaccine indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

2A Pharma is a clinical-stage biopharmaceutical company developing novel prophylactic and therapeutic vaccines based on its proprietary Adeno-Associated Virus-Like Particle (AAVLP) platform technology. The company's pipeline includes 2AP01, a broad-coverage prophylactic HPV vaccine in Phase 1 clinical trials, and 2AP07, a therapeutic vaccine targeting EpCAM+ cancers (head and neck, breast, colon, pancreatic, prostate). The platform enables vaccine design without viral genomic material, allowing safer immunogenic vaccines with broader coverage than approved alternatives.

Product overview

2A Pharma is a clinical-stage Swedish/Danish biopharmaceutical company developing novel prophylactic and therapeutic vaccines based on its patented AAVLP (adeno-associated virus-like particle) platform technology. The core platform enables vaccine development without viral genomic material, featuring two immunogenic positions for broad, cross-protective immune responses. Current portfolio includes two vaccine candidates: 2AP01 (AAVLP-HPV), a prophylactic HPV vaccine currently in Phase 1 clinical trials, and 2AP07 (AAVLP-EpCAM+), a therapeutic vaccine for EpCAM+ cancers in pre-clinical development. The platform technology can be adapted to target infectious diseases, immune-oncology, and autoimmune conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• 2AP01 (AAVLP-HPV) Prophylactic HPV vaccine candidate using the AAVLP platform technology, targeting cervical, skin, oropharyngeal and other HPV-related cancers including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in immunocompromised patients. It is the world's only L2-based HPV vaccine in clinical testing, designed to provide broader cross-protective coverage against both alpha-HPV and beta-HPV types than currently approved vaccines.
• 2AP07 (AAVLP-EpCAM+) Therapeutic vaccine candidate targeting EpCAM+ cancers including head and neck cancer, breast cancer, colon cancer, pancreatic cancer, and prostate cancer. Developed using phage display and next-generation sequencing to identify EpCAM mimotope epitopes incorporated into the AAVLP platform.

Quantifiable outcome

• Phase 1 clinical trial of AAVLP-HPV (2AP01) completed in 2020, demonstrating safety and immunological effects in healthy adult volunteers
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Medigene AGcoreTechnology or Integration · 1 January 20162A Pharma in-licensed the AAVLP technology from Medigene AG in 2016. The technology was originally discovered and developed at Medigene AG by John Nieland, Markus Hörer, and Hildegard Büning. Medigene is a biotechnology company developing innovative, complementary treatment platforms to target various types and stages of cancer, focusing on personalised T cell-based immunotherapies. 2A Pharma holds worldwide exclusive rights to develop the AAVLP technology.
• Danish Technological Institute (DTI)coreStrategic or Co-development Partner · 1 January 2016DTI (Danish Technology Institute) is a leading research and technology company that converts knowledge into value. DTI is screening several large peptide libraries to identify EpCAM mimotopes to be transferred into the AAVLP platform as part of the 2AP07 therapeutic head and neck cancer vaccine project.
• DNASensecoreTechnology or Integration · 1 January 2016DNASense makes DNA/RNA sequencing and bioinformatics accessible to life science researchers in industry and academia by converting complex data into meaningful and applicable knowledge. DNASense is performing next generation sequencing (NGS) and phage-display customized bioinformatic tools in regard to the EpCAM mimotopes for the 2AP07 project.
• Johns Hopkins UniversitycoreStrategic or Co-development PartnerJohns Hopkins University is collaborating with 2A Pharma to bring the AAVLP-HPV vaccine to market. The university is analyzing human blood samples from Phase 1 clinical trial volunteers. Johns Hopkins aims to improve the health of the community and the world by setting the standard of excellence in medical education, research, and clinical care.
• Aalborg University (AAU)coreStrategic or Co-development PartnerAalborg University has a strong collaboration with public and private sectors offering degree programmes with a real-world approach. 2A Pharma is in a research collaboration with AAU, and 2A Pharma Co-Founder Dr. John Nieland is professor at the Health Science and Technology department of the Faculty of Medicine at Aalborg University.
• Galveston National Laboratory (GNL), TexasminorStrategic or Co-development PartnerThe Galveston National Laboratory is a sophisticated high containment research facility serving as a critically important resource in the global fight against infectious diseases, known for expertise with pathogens including Ebola and COVID-19. 2A Pharma is collaborating with GNL on submitting funding applications for a pan-coronavirus vaccine as well as a pan-Ebola vaccine.
• Stony Brook UniversityminorStrategic or Co-development PartnerStony Brook University is engaged in a research collaboration with 2A Pharma on submitting funding applications for a pan-coronavirus vaccine as well as a pan-Ebola vaccine.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Moderna: mRNA vaccine platform company with active HPV and oncology vaccine programs. Not a direct VLP peer but a relevant broad incumbent shaping the competitive landscape for next-generation HPV and cancer vaccines.
• Merck & Co. (HPV / Gardasil franchise): Large pharma incumbent commercializing Gardasil/Gardasil-9, the dominant prophylactic HPV vaccines worldwide. Defines the standard of care that 2A Pharma's 2AP01 must beat on coverage or cost to gain meaningful share.

Direct peers

• Hookipa Pharma: Clinical-stage biotech developing VLP-based arenavirus and cytomegalovirus vaccine platforms for infectious disease and cancer. Closely analogous to 2A Pharma's AAVLP VLP approach and target disease areas.
• VBI Vaccines: Biotech developing enveloped VLP (eVLP) and other VLP-based vaccines targeting infectious disease and oncology, including HPV-related and cancer immunotherapy indications. Direct platform analogue to 2A Pharma's AAVLP VLP technology with comparable stage and indication overlap.
• Bavarian Nordic: European-listed vaccine biotech developing infectious disease and oncology vaccines using VLP and other platforms; headquartered in Denmark — same geography as 2A Pharma's Danish operating entity. Closely comparable in stage, business model and infectious-disease focus.
• Novavax: Clinical-stage and commercial biotech developing vaccines using a recombinant nanoparticle/VLP platform (Matrix-M adjuvant and rNV-based VLPs). Most comparable to 2A Pharma's AAVLP VLP platform in terms of technology category, scalable manufacturing approach and target indications including infectious disease and oncology vaccines.

Emerging players

• GeoVax Labs: Clinical-stage US biotech developing VLP-based vaccines for infectious disease (including HPV-related targets) and immuno-oncology. Comparable in stage, technology approach and indication overlap.
• Cue Biopharma: Clinical-stage biotech developing immunology-based therapeutics for cancer and infectious disease, including vaccine-like approaches. Comparable in stage, indication overlap (HPV-related cancers) and therapeutic vaccine positioning.
• Imugene: Clinical-stage immuno-oncology biotech developing therapeutic cancer vaccines including oncolytic virus and B-cell immunotherapy approaches. Comparable therapeutic vaccine positioning for solid tumors overlapping 2A Pharma's 2AP07 program.

Regional players

• Valneva: European-listed specialty vaccine company developing prophylactic vaccines for infectious diseases, headquartered in France/Austria with US operations. Comparable European clinical-stage vaccine developer with analogous infectious-disease focus and platform-based approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/2APharma
• LinkedInlinkedin.com/company/2a-pharma-ab
• Instagraminstagram.com/2A.pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 2A Pharma